Skip to content

Appointment of Mr. Hans Schikan to HealthCap senior advisor

HealthCap is pleased to welcome Mr. Hans Schikan as a Senior Advisor. Mr. Schikan brings more than 25 years of development, commercial and leadership experience in the (bio)pharmaceutical sector, latest as CEO of Prosensa in The Netherlands, a company focusing on rare diseases, with a lead program in Duchenne Muscular Dystrophy. During Mr. Schikan’s leadership, Prosensa was listed on NASDAQ in a successful IPO in June 2013. The company was acquired by BioMarin early 2015 for up to USD 840 million. Mr. Schikan’s previous assignments include Vice President, Marketing and Strategy Development for the rare disease portfolio of Genzyme (acquired by Sanofi) and several senior commercial roles in Organon (acquired by Schering Plough). He is currently on the board of a number of biotechnology companies in The Netherlands, Belgium, Sweden and Switzerland. He is also member of the core team of the Dutch Top Sector for Life Sciences and Health.